Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular Biosystems Inc.

This article was originally published in The Gray Sheet

Executive Summary

Non-operational subsidiary Syngene grants Abbott exclusive option to acquire rights to its proprietary diagnostic probe technology for in vitro diagnosis of infectious diseases and cancer. Under terms of the agreement, Abbott will have one year to evaluate the technology. Syngene's operations were discontinued at the end of September 1992 to allow MBI to focus on developing contrast agents for scanning devices.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel